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Abstract Since the introduction of 10-valent pneumococcal
conjugate vaccine (PCV10) into the Finnish national vaccina-
tion program in September 2010, the incidence of invasive
pneumococcal disease in children has decreased steeply in
Finland. We studied the antimicrobial susceptibility of inva-
sive and non-invasive Streptococcus pneumoniae
(pneumococcus) isolated in the Helsinki Metropolitan Area
during 2009–2014. We divided the data into two age groups:
isolates from patients <5 years old and ≥5 years old. We also
studied the serotype distribution of invasive isolates and of a
subset of non-invasive multidrug-resistant isolates. The inva-
sive isolate numbers recovered from patients aged <5 years
old declined from 33/228 (15%) in 2009 to 8/208 (4%) in
2014 (p < 0.001) and non-invasive isolate numbers declined
during the same time period from 221/595 (37%) to 119/432
(28%) (p < 0.001). At the same time, the proportion of peni-
cillin non-susceptible non-invasive isolates in this age group
decreased from 25% (56/220) to 13% (15/119) (p = 0.001) and
multidrug-resistant isolates from 22% (49/220) to 6% (7/119)
(p < 0.001), respectively. The number of PCV10 serotype
isolates also decreased among the serotyped multidrug-
resistant non-invasive isolates. Among patients aged ≥5 years
old, the isolate numbers did not show a similar decreasing
trend compared to the younger group and, further, the number
of non-PCV10 serotype isolates increased in invasive cases.
To conclude, the antimicrobial non-susceptibility of pneumo-
coccus has decreased markedly, especially among young pa-
tients (<5 years old), following PCV10 implementation in
Finland.
Introduction
Streptococcus pneumoniae (pneumococcus) causes non-
invasive respiratory tract infections and invasive infections,
such as bacteremic pneumonia, septicemia, and meningitis
[1]. Antimicrobial agents are essential in treating pneumococ-
cal infections and, before penicillin treatment became avail-
able, the mortality of pneumococcal bacteremia was over 80%
[2]. Until the late 1970s, pneumococcus was susceptible to
penicillin and other beta-lactam antimicrobials, but during
the last several decades, the rise in antimicrobial resistance
has become a global concern [3]. During the last decade, the
proportion of non-susceptible invasive isolates has also risen
in Finland. In 2010, 23% of the isolates were penicillin non-
suscep t ib le [min imum inh ib i to ry concent ra t ion
(MIC) ≥ 0.12 mg/L) [4, 5].
The polysaccharide capsule is the major pneumococcal vir-
ulence factor and over 90 pneumococcal capsular serotypes
are currently recognized [6]. A pneumococcal conjugate vac-
cine (PCV) against seven common serotypes (PCV7) causing
invasive disease in children has been available since 2000 in
the USA and since 2001 in Europe, and its effectiveness
against invasive pneumococcal disease (IPD), especially in
young children, has been well documented [7–10]. Later,
PCVs covering ten (PCV10) or thirteen (PCV13) serotypes
have been developed [11] and introduced into national vacci-
nation programs, replacing PCV7.
During 2009–2010, a large cluster-randomized PCV10 tri-
al was conducted in Finland showing the effectiveness of
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PCV10 against both culture-confirmed and clinically
suspected IPD [12, 13]. In September 2010, after a public
tender, PCV10 was introduced into the national childhood
vaccination program in Finland using a 2 + 1 schedule.
Since then, the overall incidence of IPD in vaccine-eligible
children has decreased by 80%; the incidence of IPD among
unvaccinated children has also decreased, suggesting indirect
protection [14]. The vaccination coverage has been high; ap-
proximately 95% of young children have received the full
three-dose series of vaccine, based on the statistics from the
years 2010 and 2011 [15].
The aim of the study was to investigate changes in the
antimicrobial resistance patterns of invasive and non-
invasive clinical pneumococcal isolates collected from the
Helsinki Metropolitan Area of approximately 1.8–2 million
inhabitants during 2009–2014. We also studied the serotype
distribution of the invasive isolates and of a subset of non-
invasive multidrug-resistant (MDR) isolates to assess possible
serotype replacement.
Materials and methods
Isolates and species identification
Clinical invasive (isolated from the blood or the cerebrospinal
fluid) and non-invasive (all others, e.g., from ear, eye, nose,
throat, maxillary sinus, trachea, bronchus, sputum, or abscess)
S. pneumoniae isolates from the years 2009–2014 were rou-
tinely identified at HUSLAB (Hospital District of Helsinki
and Uusimaa Laboratory Services) using optochin sensitivity
testing or matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (VITEK MS MALDI-TOF,
bioMérieux SA, Marcy l’Etoile, France). Only the first isolate
of the specific year per patient was included in the study. Both
invasive and non-invasive isolates were divided into two age
groups: isolates from patients <5 years old and ≥5 years old.
The study design is shown in Fig. 1. Of the invasive samples
positive for S. pneumoniae, 92% (1158/1254) were positive
by culture and the remaining 8% (96/1254) by the detection of
nucleic acid (AccuProbe or lytA-specific PCR [16]).
Antimicrobial susceptibility testing
Susceptibility testing was performed routinely by the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) methodology using 2014 breakpoints to
interpret the zone inhibitions or MIC breakpoints as suscepti-
ble (S), intermediate (I), or resistant (R). For invasive isolates,
susceptibilities to penicillin, erythromycin, clindamycin, cef-
triaxone, telithromycin, levofloxacin, and moxifloxacin were
mainly determined. For non-invasive isolates, susceptibilities
to penicillin, erythromycin, clindamycin, tetracycline, and
trimethoprim–sulfamethoxazole were determined. For all iso-
lates, breakpoints for infections other than meningitis were
used for benzylpenicillin (MIC S ≤ 0.06 mg/L, R > 2 mg/L),
so for this study, invasive and non-invasive isolates were cat-
egorized equally concerning SIR. Figures 2 and 4 show the
actual numbers of tested isolates for each antibiotic. Testing
was done primarily by disk diffusion (Oxoid, Cambridge,
UK) and gradient tests (Etest, bioMérieux SA, Marcy
l’Etoile, France), when appropriate. An oxacillin disk was
used to screen penicillin susceptibility and the penicillin sus-
ceptibility was verified with the gradient test when the zone
diameter was smaller than 20 mm. Multidrug resistance was
defined as non-susceptibility (I or R) to penicillin coupled
with resistance to a minimum of two other antimicrobial clas-
ses aside from beta-lactams.
Serotyping
All available invasive isolates (n = 1158) were serotyped at the
reference laboratory at the National Institute for Health and
Welfare (THL) by multiplex polymerase chain reaction
(PCR), latex agglutination, counterimmunoelectrophoresis,
or Quellung reaction [17]. Serotype data of invasive isolates
have been used partly in previous studies [4, 14]. For this
study, all available non-invasive MDR isolates (n = 84) from
the years 2009–2014 were serotyped by multiplex PCR sup-
plemented with Quellung reaction, when needed. The MDR
isolates represented all S. pneumoniaeMDR isolates from the
study years that were stored at HUSLAB and included isolates
from both age groups (<5 and ≥5 years). The serotype data
were divided into PCV10 serotypes (serotypes 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, and 23F) and non-PCV10 serotypes (all
other serotypes).
Fig. 1 Study design
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Statistical analysis
The differences in the antimicrobial non-susceptibility or se-
rotype distribution between the study years were calculated
using the Chi-square test by SPSS Statistics ver. 22.0 (IBM
Co., Armonk, NY, USA). All six years (2009–2014) were
included for analysis and a p-value <0.05 was considered
statistically significant.
Results
During 2009–2014, a total of 3040 non-invasive and 1254
invasive S. pneumoniae isolates were characterized at
HUSLAB. The median age of the non-invasive and invasive
patients was 23 years (range 0–94) and 59 years (range 0–
100), respectively. During the study years from 2009 to
2014, the number of non-invasive isolates declined by 46%
and 16% in the <5 years and ≥5 years age groups, respectively
(p < 0.001 for both). The invasive isolate number declined by
76% in the <5 years age group but increased by 2.5% in the
≥5 years age group (p < 0.001 for both). Non-invasive isolate
numbers are presented in Table 1 and invasive isolate numbers
in Table 2.
Fig. 2 a The proportion of non-susceptible non-invasive Streptococcus
pneumoniae isolates in the <5 years age group by year. b The proportion
of multidrug-resistant (MDR) and non-multidrug-resistant (non-MDR)
non-invasive S. pneumoniae isolates in the <5 years age group. c The
proportion of non-susceptible non-invasive S. pneumoniae isolates in the
≥5 years age group by year. d The proportion of multidrug-resistant
(MDR) and non-multidrug-resistant (non-MDR) non-invasive
S. pneumoniae isolates in the ≥5 years age group
Fig. 3 Serotypes of a subset of non-invasive multidrug-resistant isolates
(n = 84). Both age groups were included. PCV10 serotypes: 19F, 6B, 14,
23F (in blue and green colors); non-PCV10 serotypes: 19A, 15A, 23A (in
red, orange, and yellow colors)
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Antimicrobial susceptibility of non-invasive isolates
The non-susceptibility of the non-invasive isolates decreased
significantly for all antimicrobial classes in the <5 years age
group during the 6-year study period (Fig. 2a). The p-values
were as follows: penicillin p = 0.001, erythromycin p < 0.001,
clindamycin p = 0.002, tetracycline p = 0.003, and trimetho-
prim–sulfamethoxazole p < 0.001. The proportion of penicil-
lin non-susceptible isolates decreased from 26% (56/220) in
2009 to 13% (15/119) in 2014 and erythromycin non-
susceptible isolates from 37% (81/220) to 16% (19/119), re-
spectively. The trends for non-susceptibility to all other anti-
microbials followed a similar pattern. At the same time, the
percentage of non-invasive MDR isolates in the <5 years age
group declined significantly from 22% (49/220) in 2009 to 6%
(7/119) in 2014 (p < 0.001) (Fig. 2b). The percentage of
penicillin-resistant (MIC > 2 mg/L) isolates remained low,
around 0.9% annually.
Among the non-invasive isolates recovered from the
≥5 years age group, the changes in antimicrobial susceptibil-
ities are shown in Fig. 2c. The proportion of isolates non-
susceptible to erythromycin and trimethoprim–sulfamethoxa-
zole decreased significantly when comparing years 2009 and
2014. Erythromycin non-susceptibility was 24% (90/374) in
2009 and 18% (56/313) in 2014 (p = 0.006). Trimethoprim–
sulfamethoxazole non-susceptibility was 23% (86/373) in
Fig. 4 a The proportion of non-susceptible invasive Streptococcus
pneumoniae isolates in the <5 years age group by year. b The proportion
of multidrug-resistant (MDR) and non-multidrug-resistant (non-MDR)
invasive S. pneumoniae isolates in the <5 years age group. c The
proportion of non-susceptible invasive S. pneumoniae isolates in the
≥5 years age group by year. d The proportion of multidrug-resistant
(MDR) and non-multidrug-resistant (non-MDR) invasive S. pneumoniae
isolates in the ≥5 years age group (* = no statistical significance)
Table 1 Non-invasive Streptococcus pneumoniae isolate numbers
from each study year divided into the younger (<5 years) and older
(≥5 years) age groups
Number 2009 2010 2011 2012 2013 2014
<5 years 221 203 209 162 161 119
≥5 years 374 315 306 336 321 313
Total 595 518 515 498 482 432
Table 2 Invasive Streptococcus pneumoniae isolate numbers from
each study year divided into the younger (<5 years) and older
(≥5 years) age groups
Number 2009 2010 2011 2012 2013 2014
<5 years 33 37 27 13 13 8
≥5 years 195 200 162 182 184 200
Total 228 237 189 195 197 208
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2009 and 18% (55/311) in 2014 (p < 0.001). In this age group,
the proportion of MDR isolates remained stable during the
study period (12%; 43/373 in 2009 and 11%; 34/313 in
2014, Fig. 2d). The proportion of penicillin-resistant isolates
was approximately 0.8% annually.
Serotype distribution of non-invasive MDR isolates
We gathered all available non-invasive MDR isolates for
serotyping (n = 84, 15% of all MDR isolates; yearly, 10–
20% of the isolates were stored by deep-freezing). Forty-
four (52%) isolates were from patients <5 years old and 40
(48%) isolates were from patients ≥5 years old. Both
PCV10 serotypes (19F, 6B, 14, 23F) and non-PCV10 se-
rotypes (19A, 15A, 23A) were discovered among these
isolates (Fig. 3). The proportion of PCV10 serotypes de-
clined from 82% (18/22) in 2009 to 33% (2/6) in 2014
(p < 0.001), while the number of non-PCV10 serotypes
did not change.
Antimicrobial susceptibility of invasive isolates
The number of invasive isolates in the <5 years age group was
small (n = 131) and no statistically significant changes were
observed between the study years when comparing antimicro-
bial susceptibilities or proportions of MDR isolates (Fig. 4a,
b). There were no penicillin-resistant isolates in this group.
The proportion of MDR isolates was 9.4% (3/32) in 2009
and 25% (2/8) in 2014, but the difference was not statistically
significant due to the low isolates number (Fig. 4b).
Among invasive isolates in the ≥5 years age group, non-
susceptibility decreased significantly for erythromycin
(p < 0.001) and telithromycin (p < 0.001) when comparing
years 2009 and 2014 (Fig. 4c). For all other antimicrobial
classes, no significant decreasing trends were detected. The
annual proportion of penicillin-resistant isolates was 0.2%
during the study period. The proportion of MDR isolates de-
creased from 4.3% (8/184) in 2009 to 1.6% (3/184) in 2014,
but the change was not statistically significant (Fig. 4d).
Serotype distribution of invasive isolates
In the <5 years age group, the proportion of PCV10 serotypes
decreased among invasive isolates from 70% (21/30) in 2009
to 13% (1/8) in 2014 (p < 0.001), while the number of non-
PCV10 serotype isolates remained stable (Fig. 5a). Twelve
different non-PCV10 serotypes were observed and, of these,
serotype 19Awas the most frequent, representing 38% (15/39)
of all non-PCV10 serotypes in the study years. After serotype
19A, serotypes 3 (13%; 5/39) and 6A (13%; 5/39) were the
second most frequent. In the ≥5 years age group, the propor-
tion of PCV10 serotype isolates decreased from 63% (112/
177) in 2009 to 28% (52/183) in 2014 (p < 0.001). At the
same time, the number of non-PCV10 serotype isolates in-
creased from 65 (37% of 177 isolates) in 2009 to 131 (72%
of 183 isolates) in 2014 (p < 0.001) (Fig. 5b). In this age
group, 32 different non-PCV10 serotypes were observed in
the study years. The three most frequent non-PCV10 sero-
types were serotypes 3 (23%; 115/501), 22F (16%; 79/501),
and 19A (12%; 61/501). The trend for all three of these sero-
types was increasing when comparing years 2009 and 2014.
Discussion
We studied the antimicrobial susceptibility of invasive and
non-invasive pneumococcal isolates during 2009–2014 in
the Helsinki Metropolitan Area, Finland, and found a sig-
nificant decrease in non-susceptibility, especially in non-
invasive isolates, after the introduction of PCV10 into the
Fig. 5 a The number of invasive isolates in the <5 years age group by serotype group and study year. b The number of invasive isolates in the ≥5 years
age group by serotype group and study year
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national childhood vaccination program in 2010. Before
PCV10 introduction, pneumococcal antimicrobial resis-
tance was highest in non-invasive isolates of children
<5 years old; 22% of the isolates were MDR. In 2014, four
years after PCV10 introduction, non-susceptibility for all
four tested antimicrobial classes (penicillin, macrolides,
tetracycline, and trimethoprim–sulfamethoxazole) in these
isolates had decreased and only 6% were MDR. This indi-
cates a beneficial impact of the PCV10 vaccination. The
annual percentage of penicillin resistance (MIC > 2 mg/L)
was low (0.9%) compared to many other countries in
Europe [18].
Hauser et al. [19] studied the impact of PCV7 and PCV13
vaccines on the pneumococcal antimicrobial susceptibility in
Switzerland. They also found that antimicrobial non-
susceptibility was highest in children <5 years old and vaccine
introduction caused improvement of pneumococcal penicillin,
erythromycin, and trimethoprim–sulfamethoxazole suscepti-
bility in this age group. In a Brazilian study, PCV10 vaccina-
tion improved pneumococcal penicillin susceptibility in all
age groups and, additionally, susceptibility to trimethoprim–
sulfamethoxazole in the <15 years age group [20]. However,
comparisons to our study are not straightforward, as the study
from Brazil described the susceptibility of only 259 invasive
isolates.
In this study, non-susceptibility of non-invasive isolates for
erythromycin, tetracycline, and trimethoprim–sulfamethoxa-
zole decreased also in the ≥5 years age group. Although the
susceptibility to penicillin did not change during the study
period, these changes probably reflect the indirect effect of
the PCV10 vaccine on pneumococcal antimicrobial suscepti-
bilities among older patients.
The antimicrobial susceptibility data used in this study
were comprehensive and covered both invasive and non-
invasive isolates collected at the HUSLAB from the
Helsinki Metropolitan Area, where almost a third of the
Finnish population lives. In the Hospital District of Helsinki
and Uusimaa, the methods and guidelines to diagnose and
treat pneumococcal diseases have remained the same during
the studied years and, thus, we conclude that our results likely
reflect true changes caused by the vaccination, rather than
changes in diagnostic or clinical practices. After the start of
PCV10 vaccination, the outpatient antimicrobial purchase
numbers have also decreased in the vaccinated child popula-
tion in Finland [21]. In addition to directly reducing or elim-
inating pneumococcal disease caused by antimicrobial non-
susceptible PCV10 serotypes, the subsequent reduction in an-
timicrobial consumption and, hence, reduced antimicrobial
selection pressure may also discourage the development of
resistance in pneumococci in the human respiratory tract.
Both invasive and non-invasive pneumococcal isolate num-
bers declined in the <5 years age group, suggesting reduced
disease burden.
Our serotype data of invasive isolates were comprehensive
and collected continuously by the National Institute for Health
and Welfare for surveillance. In the younger age group
(<5 years), the PCV10 serotypes almost disappeared, but the
number of non-PCV10 serotype isolates remained stable
throughout the study period. dos Santos et al. have described
similar results in patients <2 years old in Brazil after PCV10
introduction, but the follow-up time in that study was only 2
years [20]. In our study, the PCV10 serotypes decreased also
among invasive isolates from older patients (≥5 years). Since
PCV vaccination has not been routinely used in Finland for
the elderly population, these patients may represent mostly the
unvaccinated population and, thus, the reduction in IPD was
most likely due to herd protection [22]. At the same time, the
number of non-PCV10 serotype isolates increased in this age
group, resulting in a stable total number of invasive isolates
during the whole study period. This rise was most pronounced
in 2014. A longer surveillance will show if the change
continues.
To estimate reliably changes in the serotype distribution of
non-invasiveMDR isolates, more data would be needed, since
our subset represented only 10–20% of the MDR isolates.
However, it offers a view of possible changes that may have
taken place in the serotype distribution of non-invasive iso-
lates since the large-scale use of PCV10. Our findings suggest
that PCV10 serotypes have decreased also among these iso-
lates. It will be interesting to follow up how long this may last
and if the proportion of resistant non-PCV10 serotype isolates,
such as 19A, will increase in the future. Increased incidence of
serotype 19A and other non-PCV7 serotype isolates has been
shown after PCV7 introduction in the USA, the Netherlands,
and many other countries [23, 24]. In France, the prevalence
of antimicrobial-resistant pneumococci decreased after
PCV13 introduction and was mainly driven by the decline
of the serotype 19A [25].
Finally, we conclude that, due to PCV10 vaccination, in-
vasive pneumococcal infections have almost disappeared
among patients <5 years old and the non-susceptibility of
non-invasive pneumococcal isolates in this age group has de-
creased for all antimicrobial classes. Serotype replacement
phenomenon has presumably begun in invasive isolates
among patients ≥5 years old, but further surveillance is
needed.
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